Paper6366128
Phase I study of carboplatin given on a five-day intravenous schedule.
Rozencweig M and 6 others. J Clin Oncol, 1983. Cited by 65 papers, by iCite.
Cite this record
ConductScience Library. Phase I study of carboplatin given on a five-day intravenous schedule. Papers, record 6366128. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6366128
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Neoplasms | Major topic |
| Organoplatinum Compounds | Major topic |
| Adult | |
| Aged | |
| Carboplatin | |
| Drug Administration Schedule | |
| Drug Evaluation | |
| Female | |
| Hematologic Diseases | |
| Humans | |
| Infusions, Parenteral | |
| Kidney Diseases | |
| Male | |
| Middle Aged |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| N01-CM 53840 | NCI NIH HHS | United States | N01CM053840 | PubMed and NIH |
Source NIH RePORTER
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 65 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 30666153 | Efficacy and tolerability of BP-C1 in metastatic breast cancer: a Phase II, randomized, double-blind, and placebo-controlled Thai multi-center study. | Breast Cancer (Dove Med Press) | 2019 | https://conductscience.org/library/papers/30666153 | PubMed |
| 26061351 | Pharmacokinetics and tissue distribution of novel platinum containing anticancer agent BP-C1 studied in rabbits using sector field inductively coupled plasma mass spectrometry. | Drug Test Anal | 2015 | https://conductscience.org/library/papers/26061351 | PubMed |
| 24234333 | Feasibility and safety of carboplatin plus paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer: a pilot study. | Tumour Biol | 2014 | https://conductscience.org/library/papers/24234333 | PubMed |
| 9738983 | Release of cytokines from human umbilical vein endothelial cells treated with platinum compounds in vitro. | Jpn J Cancer Res | 1998 | https://conductscience.org/library/papers/9738983 | PubMed |
| 9247610 | Pharmacokinetic study of carboplatin given on a 5-day intravenous schedule. | Jpn J Cancer Res | 1997 | https://conductscience.org/library/papers/9247610 | PubMed |
| 8431374 | A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days. | Br J Cancer | 1993 | https://conductscience.org/library/papers/8431374 | PubMed |
| 8258189 | Combination treatment of cis- and carboplatin in cancers restricted to the peritoneal cavity in the rat. | Cancer Chemother Pharmacol | 1993 | https://conductscience.org/library/papers/8258189 | PubMed |
| 6392147 | A phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule. | Invest New Drugs | 1984 | https://conductscience.org/library/papers/6392147 | PubMed |
| 3525449 | A phase II study of carboplatin in advanced squamous cell carcinoma of the cervix (a Gynecologic Oncology Group Study). | Invest New Drugs | 1986 | https://conductscience.org/library/papers/3525449 | PubMed |
| 3516429 | High-performance liquid chromatographic procedures for the analysis of carboplatin in human plasma and urine. | Cancer Chemother Pharmacol | 1986 | https://conductscience.org/library/papers/3516429 | PubMed |
| 2679841 | Acute and cumulative effects of carboplatin on renal function. | Br J Cancer | 1989 | https://conductscience.org/library/papers/2679841 | PubMed |
| 2650904 | Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients. | Cancer Chemother Pharmacol | 1989 | https://conductscience.org/library/papers/2650904 | PubMed |
| 2649354 | Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. | Drugs | 1989 | https://conductscience.org/library/papers/2649354 | PubMed |
| 2191847 | Antineoplastic drugs in 1990. A review (Part II). | Drugs | 1990 | https://conductscience.org/library/papers/2191847 | PubMed |
| 2183874 | Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive days. | Br J Cancer | 1990 | https://conductscience.org/library/papers/2183874 | PubMed |
| 2178792 | A strategy for the development of two clinically active cisplatin analogs: CBDCA and CHIP. | Cancer Chemother Pharmacol | 1990 | https://conductscience.org/library/papers/2178792 | PubMed |
| 2155064 | Etoposide, carboplatin, cyclophosphamide and vincristine in previously untreated patients with small-cell lung cancer. | Cancer Chemother Pharmacol | 1990 | https://conductscience.org/library/papers/2155064 | PubMed |
| 2114395 | Advantages in combination chemotherapy using cisplatin and its analogues for human testicular tumor xenografts. | Jpn J Cancer Res | 1990 | https://conductscience.org/library/papers/2114395 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6366128
GET https://conductscience.org/api/papers/v1/6366128/authors